STRO - Sutro Biopharma Inc Stock Price, Fair Value and News

4.00USD-0.15 (-3.61%)Market Closed

Market Summary

USD4.00-0.15

Market Closed

-3.61%

STRO Stock Price

View Fullscreen

STRO RSI Chart

STRO Valuation

Market Cap

327.2M

Price/Earnings (Trailing)

-2.85

Price/Sales (Trailing)

2.12

EV/EBITDA

-2.93

Price/Free Cashflow

-2.84

STRO Price/Sales (Trailing)

STRO Profitability

EBT Margin

-63.06%

Return on Equity

-117.27%

Return on Assets

-28.5%

Free Cashflow Yield

-35.26%

STRO Fundamentals

STRO Revenue

Revenue (TTM)

154.1M

Rev. Growth (Yr)

2.64%

Rev. Growth (Qtr)

-88.56%

STRO Earnings

Earnings (TTM)

-115.0M

Earnings Growth (Yr)

-16.31%

Earnings Growth (Qtr)

-287.39%

Breaking Down STRO Revenue

Last 7 days

-3.6%

Last 30 days

5.3%

Last 90 days

-7.6%

Trailing 12 Months

-24.4%

How does STRO drawdown profile look like?

STRO Financial Health

Current Ratio

4.46

STRO Investor Care

Shares Dilution (1Y)

35.38%

Diluted EPS (TTM)

-1.88

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	154.1M	0	0	0
2023	74.5M	56.9M	48.6M	153.7M
2022	53.1M	53.2M	69.8M	67.8M
2021	50.2M	68.8M	59.5M	61.9M
2020	41.3M	40.2M	45.7M	42.7M
2019	41.3M	46.1M	50.5M	42.7M
2018	41.0M	31.3M	21.7M	36.7M
2017	57.7M	55.7M	53.7M	51.7M
2016	0	0	0	59.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Sutro Biopharma Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 01, 2024	srinivasan venkatesh	sold (taxes)	-3,336	3.74	-892	chief tech op officer
May 01, 2024	srinivasan venkatesh	acquired	-	-	2,500	chief tech op officer
Apr 11, 2024	srinivasan venkatesh	acquired	-	-	21,250	chief tech op officer
Apr 11, 2024	srinivasan venkatesh	sold (taxes)	-34,119	4.5	-7,582	chief tech op officer
Mar 05, 2024	albini edward c	sold (taxes)	-14,074	4.54	-3,100	cfo and secretary
Mar 05, 2024	albini edward c	acquired	-	-	8,750	cfo and secretary
Mar 05, 2024	fitzpatrick linda a	acquired	-	-	8,750	chief people & comm. officer
Mar 05, 2024	fitzpatrick linda a	sold (taxes)	-14,110	4.54	-3,108	chief people & comm. officer
Mar 05, 2024	newell william j	acquired	-	-	18,750	ceo
Mar 05, 2024	newell william j	sold (taxes)	-30,372	4.54	-6,690	ceo

Which funds bought or sold STRO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-29.38	-31,687	421,711	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.14	-7,870	34,601	-%
May 16, 2024	COMERICA BANK	reduced	-73.8	-525	277	-%
May 15, 2024	Exome Asset Management LLC	sold off	-100	-658,944	-	-%
May 15, 2024	Schonfeld Strategic Advisors LLC	added	231	4,892,920	6,345,520	0.04%
May 15, 2024	Squarepoint Ops LLC	sold off	-100	-59,644	-	-%
May 15, 2024	DAFNA Capital Management LLC	added	18.02	673,137	1,887,550	0.43%
May 15, 2024	STATE STREET CORP	added	3.04	1,778,800	6,761,480	-%
May 15, 2024	Walleye Capital LLC	sold off	-100	-314,333	-	-%
May 15, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	reduced	-79.72	-168,317	61,348	-%

Are Funds Buying or Selling STRO?

Are funds buying STRO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own STRO

No. of Funds

Unveiling Sutro Biopharma Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 05, 2024	point72 asset management, l.p.	7.7%	5,791,505	SC 13G
Feb 13, 2024	suvretta capital management, llc	9.5%	5,778,188	SC 13G/A
Feb 12, 2024	rubric capital management lp	5.49%	3,344,810	SC 13G/A
Feb 07, 2024	adage capital partners gp, l.l.c.	7.33%	4,467,796	SC 13G/A
Jan 24, 2024	blackrock inc.	9.6%	5,823,922	SC 13G/A
Jan 17, 2024	integrated core strategies (us) llc	5.1%	3,106,844	SC 13G
Oct 10, 2023	adage capital partners gp, l.l.c.	5.86%	3,549,320	SC 13G
Feb 14, 2023	eventide asset management, llc	0%	0	SC 13G/A
Feb 14, 2023	biotechnology value fund l p	3.1%	1,801,709	SC 13G/A
Feb 13, 2023	suvretta capital management, llc	9.7%	5,565,099	SC 13G/A

Recent SEC filings of Sutro Biopharma Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	DEFA14A	DEFA14A
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
May 03, 2024	4	Insider Trading
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 12, 2024	4	Insider Trading
Apr 05, 2024	SC 13G	Major Ownership Report
Apr 02, 2024	424B5	Prospectus Filed

Peers (Alternatives to Sutro Biopharma Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Sutro Biopharma Inc News

Latest updates

Sutro Biopharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-88.6%	13,008,000	113,721,000	16,924,000	10,412,000	12,674,000	8,632,000	25,147,000	28,096,000	5,897,000	10,654,000	8,517,000	28,049,000	14,660,000	8,278,000	17,823,000	9,469,000	7,152,000	11,305,000	12,277,000	10,525,000	8,629,000
Operating Expenses	-1.4%	69,599,000	70,569,000	60,938,000	56,591,000	54,911,000	57,854,000	46,357,000	47,475,000	45,029,000	45,690,000	43,191,000	37,854,000	33,669,000	33,121,000	28,440,000	25,886,000	26,332,000	26,087,000	25,012,000	24,210,000	22,895,000
S&GA Expenses	-100.0%	-	16,804,000	15,269,000	14,999,000	15,512,000	14,719,000	14,643,000	15,143,000	15,039,000	15,763,000	16,589,000	12,545,000	11,107,000	10,383,000	9,079,000	8,643,000	8,713,000	8,695,000	8,115,000	8,067,000	7,715,000
R&D Expenses	5.8%	56,878,000	53,765,000	45,669,000	41,592,000	39,399,000	43,135,000	31,714,000	32,332,000	29,990,000	29,927,000	26,602,000	25,309,000	22,562,000	22,738,000	19,361,000	17,243,000	17,619,000	17,392,000	16,897,000	16,143,000	15,180,000
EBITDA Margin	-10.6%	-0.58	-0.52	-3.33	-2.36	-1.60	-1.61	-1.62	-2.34	-2.02	-1.59	-0.42	-0.37	-0.51	-	-	-	-	-	-	-	-
Interest Expenses	-59.4%	63,000	155,000	249,000	329,000	393,000	427,000	444,000	494,000	504,000	510,000	516,000	689,000	331,000	510,000	516,000	515,000	134,000	151,000	265,000	303,000	330,000
Income Taxes	-99.9%	10,000	15,780,500	1,839,000	200,000	400,000	-	-	2,500,000	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-224.2%	-58,213,000	46,872,000	-47,445,000	-38,373,000	-49,655,000	-34,594,000	-19,488,000	-23,512,000	-39,110,000	-38,125,000	-30,902,000	-6,152,000	-	-	-	-	-	-	-	-	-
EBT Margin	-9.4%	-0.63	-0.58	-3.50	-2.50	-1.71	-1.72	-1.72	-2.48	-2.15	-1.71	-0.54	-0.47	-0.64	-	-	-	-	-	-	-	-
Net Income	-287.4%	-58,213,000	31,065,000	-49,284,000	-38,524,000	-50,050,000	-34,594,000	-19,488,000	-26,012,000	-39,110,000	-38,125,000	-30,902,000	-6,152,000	-30,359,000	-59,544,000	17,139,000	29,872,000	-19,595,000	-14,789,000	-12,912,000	-13,793,000	-14,250,000
Net Income Margin	-7.4%	-0.75	-0.69	-3.55	-2.51	-1.75	-1.76	-1.76	-2.52	-2.15	-1.71	-2.13	-1.15	-0.85	-	-	-	-	-	-	-	-
Free Cashflow	-560.1%	-64,741,000	14,072,000	-34,265,000	-31,958,000	-61,754,000	-24,627,000	65,091,000	-3,949,000	-36,018,000	-22,343,000	-25,169,000	-6,026,000	-31,193,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-14.3%	403	471	432	465	358	407	401	386	304	341	371	360	359	394	307	278	154	156	172	189	202
Current Assets	-15.9%	355	422	381	412	304	353	347	332	229	219	251	278	266	378	292	258	127	129	136	162	177
Cash Equivalents	-5.8%	65.00	69.00	82.00	235	62.00	47.00	97.00	79.00	29.00	30.00	31.00	56.00	56.00	206	64.00	65.00	44.00	5.00	12.00	19.00	27.00
Net PPE	-6.0%	21.00	22.00	22.00	24.00	24.00	25.00	24.00	24.00	23.00	23.00	23.00	19.00	15.00	13.00	12.00	11.00	10.00	10.00	9.00	9.00	10.00
Liabilities	-4.9%	305	321	319	310	173	190	171	177	83.00	89.00	88.00	52.00	51.00	62.00	63.00	71.00	72.00	59.00	62.00	69.00	72.00
Current Liabilities	-15.2%	80.00	94.00	74.00	67.00	59.00	67.00	58.00	45.00	39.00	42.00	35.00	26.00	23.00	30.00	30.00	35.00	32.00	33.00	36.00	36.00	31.00
Long Term Debt	-	-	-	-	-	-	4.00	7.00	10.00	13.00	16.00	19.00	22.00	25.00	25.00	24.00	24.00	24.00	9.00	6.00	7.00	9.00
LT Debt, Non Current	-	-	-	-	-	-	4.00	7.00	10.00	13.00	16.00	19.00	22.00	25.00	25.00	24.00	24.00	24.00	9.00	6.00	7.00	9.00
Shareholder's Equity	-34.5%	98.00	150	112	155	185	217	230	209	220	253	284	308	307	332	244	207	82.00	98.00	110	120	131
Retained Earnings	-10.4%	-617	-559	-590	-541	-502	-452	-418	-398	-372	-333	-295	-264	-258	-227	-168	-185	-215	-195	-180	-168	-154
Additional Paid-In Capital	0.9%	716	709	703	696	688	670	649	609	594	586	579	572	566	560	412	392	297	293	291	287	285
Shares Outstanding	2.3%	62.00	61.00	61.00	60.00	60.00	57.00	49.00	47.00	46.00	46.00	46.00	46.00	46.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	278	-	-	-	251	-	-	-	850	-	-	-	261	-	-	-	236	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-560.1%	-64,741	14,072	-33,502	-31,195	-60,991	-23,864	65,854	-3,186	-35,255	-21,580	-24,406	-5,263	-30,430	-18,879	-17,689	-12,500	-18,734	-13,156	-16,121	-15,601	-20,145
Share Based Compensation	-2.5%	6,068	6,223	6,003	6,661	6,021	5,852	6,782	6,696	6,974	6,887	6,495	5,907	3,952	3,087	3,112	3,011	2,707	2,683	2,880	2,463	2,286
Cashflow From Investing	372.6%	64,105	-23,513	-114,019	66,157	67,451	-37,882	-78,037	47,915	32,982	20,781	-2,242	5,876	-121,730	15,807	296	-57,136	41,637	7,942	9,812	9,194	-78,079
Cashflow From Financing	-9.7%	-3,429	-3,125	-5,740	137,661	8,758	12,221	29,847	5,485	760	506	963	-39.00	1,826	144,854	17,272	91,419	15,702	-1,780	-1,127	-819	-458

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

STRO Income Statement

2024-03-31

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 13,008	$ 12,674
Operating expenses
Research and development	56,878	39,399
General and administrative	12,721	15,512
Total operating expenses	69,599	54,911
Loss from operations	(56,591)	(42,237)
Interest income	4,096	2,560
Unrealized gain (loss) on equity securities	3,679	(6,992)
Non-cash interest expense related to the sale of future royalties	(7,184)
Interest and other income (expense), net	(2,213)	(2,986)
Loss before provision for income taxes	(58,213)	(49,655)
Provision for income taxes		395
Net loss	$ (58,213)	$ (50,050)
Net loss per share, basic	$ (0.95)	$ (0.85)
Net loss per share, diluted	$ (0.95)	$ (0.85)
Weighted-average shares used in computing basic net loss per share	61,457,793	58,723,432
Weighted-average shares used in computing diluted net loss per share	61,457,793	58,723,432

STRO Balance Sheet

2024-03-31

Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 65,218	$ 69,268
Marketable securities	202,384	264,413
Investment in equity securities	45,616	41,937
Accounts receivable	31,300	36,078
Prepaid expenses and other current assets	10,064	9,846
Total current assets	354,582	421,542
Property and equipment, net	20,630	21,940
Operating lease right-of-use assets	21,594	22,815
Marketable securities, non-current	0	0
Other non-current assets	5,739	3,567
Restricted cash	857	872
Total assets	403,402	470,736
Current liabilities:
Accounts payable	7,511	9,440
Accrued compensation	7,077	14,686
Deferred revenue—current	20,502	20,666
Operating lease liability - current	6,673	6,420
Debt—current		4,061
Accrued expenses and other current liabilities	37,746	38,473
Total current liabilities	79,509	93,746
Deferred revenue - non-current	46,313	53,379
Operating lease liability - non-current	21,397	23,154
Deferred royalty obligation related to the sale of future royalties	156,465	149,114
Other non-current liabilities	1,694	1,694
Total liabilities	305,378	321,087
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.001 par value -10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued and outstanding as of March 31, 2024 and December 31, 2023
Common stock, $0.001 par value - 300,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 62,456,546 and61,009,829 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	62	61
Additional paid-in-capital	715,696	708,975
Accumulated other comprehensive income (loss)	(113)	21
Accumulated deficit	(617,621)	(559,408)
Total stockholders’ equity	98,024	149,649
Total Liabilities and Stockholders’ Equity	$ 403,402	$ 470,736

About Sutro Biopharma Inc

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. Its pre-clinical product candidate STRO-003, a ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

CEO	Mr. William J. Newell J.D.
WEBSITE	sutrobio.com
INDUSTRY	Biotechnology
EMPLOYEES	297

Sutro Biopharma Inc Frequently Asked Questions

What is the ticker symbol for Sutro Biopharma Inc? What does STRO stand for in stocks?

STRO is the stock ticker symbol of Sutro Biopharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sutro Biopharma Inc (STRO)?

As of Fri May 17 2024, market cap of Sutro Biopharma Inc is 327.18 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of STRO stock?

You can check STRO's fair value in chart for subscribers.

What is the fair value of STRO stock?

You can check STRO's fair value in chart for subscribers. The fair value of Sutro Biopharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Sutro Biopharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for STRO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Sutro Biopharma Inc a good stock to buy?

The fair value guage provides a quick view whether STRO is over valued or under valued. Whether Sutro Biopharma Inc is cheap or expensive depends on the assumptions which impact Sutro Biopharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for STRO.

What is Sutro Biopharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, STRO's PE ratio (Price to Earnings) is -2.85 and Price to Sales (PS) ratio is 2.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. STRO PE ratio will change depending on the future growth rate expectations of investors.